JP2008115143A - Vitamin d compound-containing active hydrogen water - Google Patents
Vitamin d compound-containing active hydrogen water Download PDFInfo
- Publication number
- JP2008115143A JP2008115143A JP2006326308A JP2006326308A JP2008115143A JP 2008115143 A JP2008115143 A JP 2008115143A JP 2006326308 A JP2006326308 A JP 2006326308A JP 2006326308 A JP2006326308 A JP 2006326308A JP 2008115143 A JP2008115143 A JP 2008115143A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- active hydrogen
- compound
- hydrogen water
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 229910052739 hydrogen Inorganic materials 0.000 title claims abstract description 59
- 239000001257 hydrogen Substances 0.000 title claims abstract description 59
- 229940046008 vitamin d Drugs 0.000 title claims abstract description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 title 1
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 52
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 52
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 52
- 239000011710 vitamin D Substances 0.000 claims abstract description 52
- -1 vitamin D compound Chemical class 0.000 claims abstract description 39
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 17
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 abstract description 27
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 16
- 229910052760 oxygen Inorganic materials 0.000 abstract description 16
- 239000001301 oxygen Substances 0.000 abstract description 16
- 208000024891 symptom Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 22
- 230000003647 oxidation Effects 0.000 description 12
- 238000007254 oxidation reaction Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000017520 skin disease Diseases 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000007785 kidney angiomyolipoma Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000018677 Skin and Connective Tissue disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 101150034786 Tsc2 gene Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003924 oil dispersant Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 101150091591 tsc1 gene Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、結節性硬化症の諸症状やガン腫瘍などの成長を抑えるのに有効な体質改善用飲料用に用いられるビタミンD化合物含有活性水素水
に関する。The present invention relates to an active hydrogen water containing a vitamin D compound used for a constitution improving drink effective for suppressing the growth of various symptoms of tuberous sclerosis and cancer tumors.
従来、結節硬化症の体質改善のための技術はほとんど進歩がみられないが、ガンや成人病や難病には活性水素水が効果的だと言われ、それによって活性水素水を生成する技術が数多く見られている。 Conventionally, there has been little progress in technology for improving the constitution of tuberous sclerosis, but active hydrogen water is said to be effective for cancer, adult diseases, and intractable diseases. Many have been seen.
ビタミンD化合物は人の体内の皮膚で紫外線に当たることでビタミンD3となる。従来から、結節性硬化症(プリングル病)への治療薬にビタミンD3が用いられていたが、この病気の患者数が絶対的に少ないために本やインターネットで調べてみても、この病気についてあまり研究が進んでいないのが現状である。Vitamin D compounds become vitamin D 3 when exposed to ultraviolet rays in the skin of the human body. Traditionally, vitamin D 3 has been used as a treatment for tuberous sclerosis (Pringle disease), but the number of patients with this disease is absolutely small, so even if you look it up in books or on the Internet, there is not much about this disease. Currently, research is not progressing.
ここでビタミンD化合物の体内での働きを先に述べておきたい。
(1)水素水と共に体内に運ばれたビタミンD化合物は,ホルモンとして働くいくつかの活性化代謝物をもつプロホルモンである。
(2)ビタミンD3前駆物質は,皮膚で7−デヒドロコレステロールから光化学的に合成されゆっくりとビタミンD3に異性化された後、ビタミンD結合蛋白によって取り除かれる。
(3)ビタミンDはコレステロール生合成の中間体であり、皮膚細胞に一緒に運ばれたプロビタミンD3が皮下で紫外線によってビタミンD3となり、色素定着が行われる。
(4)その後肝臓、腎臓を経て活性型ビタミンD3として作用する。
(5)ビタミンD3は、肝臓において、血液中に存在する主な形態である25−OHビタミンDに転化される。
(6)腎臓で水酸化を受けた結果生じる代謝産物が1.25ジヒドロキシビタミンD3(1.25(OH)2D3で、ビタミンD代謝物の中で最も高い生理活性を示す。ビタミンDは腸からカルシウムとリンの吸収を助け骨に対するカルシウム基の沈着を良くする。
上記を参考文献として利用した文献としては
「有機って面白いよね!」より 有機工業化学
妹尾学、田村利武、平井長一郎、飯田隆 共立出版株式会社Here, I would like to describe the action of vitamin D compounds in the body first.
(1) The vitamin D compound carried into the body together with hydrogen water is a prohormone having several activated metabolites that act as hormones.
(2) Vitamin D 3 precursor is photochemically synthesized from 7-dehydrocholesterol in the skin and slowly isomerized to vitamin D 3 and then removed by vitamin D binding protein.
(3) Vitamin D is an intermediate in cholesterol biosynthesis, provitamin D 3 carried along the skin cells next to vitamin D 3 by ultraviolet subcutaneously, dye fixing takes place.
(4) Then, it acts as active vitamin D 3 via the liver and kidney.
(5) Vitamin D 3 is converted in the liver to 25-OH vitamin D, which is the main form present in blood.
(6) The metabolite resulting from hydroxylation in the kidney is 1.25 dihydroxyvitamin D 3 (1.25 (OH) 2 D 3 , which shows the highest physiological activity among vitamin D metabolites. Vitamin D Helps the absorption of calcium and phosphorus from the intestine and improves the deposition of calcium groups on the bones.
As a reference using the above as a reference, “Organic is interesting!” Organic Industrial Chemistry Senao Manabu, Tamura Toshitake, Hirai Choichiro, Iida Takashi Kyoritsu Publishing Co., Ltd.
AP通信によると、ビタミンDの摂取と肺ガンの生存率との間に相関関係があることを示す研究成果が発表された。デビッド・クリスチャーニ・ハーバード大学教授のグループは、マサチューセッツ・ジェネラル病院などの初期肺ガン患者456人を対象に、食事やサプリメント、肺ガン手術の時期について聞き取り調査を行った。その結果、ビタミンDの摂取量が多く、夏に手術した患者の5年生存率が72%だったのに対し、同摂取量が少なく、冬に手術した患者では29%だった。ビタミンDは、皮膚が日光に当たることによって作られることから、手術前後にビタミンDを多く摂取すれば肺ガン生存率を上げられる可能性があると発表されている。According to AP, research results have been shown to show a correlation between vitamin D intake and lung cancer survival. A group of professors from David Christiani Harvard interviewed 456 early lung cancer patients such as Massachusetts General Hospital about the timing of diet, supplements, and lung cancer surgery. As a result, the intake of vitamin D was high, and the 5-year survival rate for patients operated in summer was 72%, while that for those operated in winter was 29%. Since vitamin D is produced by exposure of the skin to sunlight, it has been announced that if a large amount of vitamin D is taken before and after surgery, the survival rate of lung cancer may be increased.
ビタミンDは、大腸ガンの予防にも効果がある。高脂肪の食事をすると肝臓から胆汁酸が出る。このうち「リトコール酸」は、動物の腸管に高濃度であると、大腸ガンを起こす。ところが、ビタミンDを与えた後、リトコール酸を与えたら動物に大腸ガンは起きなかったのである。すなわち、ビタミンDにはリトコール酸を解毒させる働きがあるという。
参考文献 米科学誌「サイエンス」より
テキサス・サウスウエスタン大学ハワードヒューズ医学センターのデービッド・マンゲルスドーフ博士。Vitamin D is also effective in preventing colorectal cancer. When you eat a high-fat diet, bile acids come out of the liver. Among these, “lithocholic acid” causes colon cancer at high concentrations in the intestinal tract of animals. However, if lithocholic acid was given after vitamin D, colon cancer did not occur in the animals. That is, vitamin D has a function of detoxifying lithocholic acid.
References Dr. David Mangersdorf, University of Texas Southwestern Howard Hughes Medical Center, from the US science journal Science.
結節性硬化症の腫瘍による主な症状としては「肺・心臓・腎臓・眼底の腫瘍 顔面・背中の脂腺腫による視力障害・視野障害・呼吸器障害・循環器障害・皮膚障害、てんかんその他の痙攣発作、知能低下、精神神経症状」があげられる。
結節性硬化症の症状に多い腫瘍は5〜10年の年月をかけて大きくなる。そもそもガン細胞は、体内の活性酸素(他の物質と結合しやすい性質の原子や分子の状態の酸素)が何らかの関与をしていると言われている。また、活性酸素の発生は、食習慣や生活環境、運動不足、ストレス、有害物質の摂取による免疫力の低下によると考えられている。
さらに10年の間にもその活性酸素が腫瘍細胞を成長させる促進剤になっていると言われている。したがって、活性酸素が体内に多量に残存しているうちは、どんな栄養剤を投与しても十分な効果を得難い。Major symptoms of tuberous sclerosis tumors include: “Lung / heart / kidney / fundus tumors / face / back sebaceous glands / vision / vision / respiratory / cardiovascular / skin disorders, epilepsy and other convulsions Seizures, reduced intelligence, and neuropsychiatric symptoms ”.
Tumors that are common in the symptoms of tuberous sclerosis grow over 5-10 years. In the first place, cancer cells are said to be involved in some kind of active oxygen in the body (oxygen in the state of atoms or molecules that easily bind to other substances). The generation of active oxygen is considered to be due to a decrease in immunity due to eating habits, living environment, lack of exercise, stress, and intake of harmful substances.
Furthermore, it is said that the active oxygen has been an accelerator for growing tumor cells for 10 years. Therefore, as long as active oxygen remains in the body, it is difficult to obtain a sufficient effect no matter what nutrient is administered.
結節性硬化症の治療策として、ただ真っ白な部屋で何も考えず何も刺激を与えず何もストレスを感じないように寝ることと医師は言うが、現代において金銭的にも精神的にもそのような養生が全ての結節性硬化症患者にとって有効でないことは明らかである。 As a treatment for tuberous sclerosis, doctors say that they sleep in a pure white room without thinking anything and giving no stimulus and feeling no stress, but in modern times both financially and mentally It is clear that such a regimen is not effective for all tuberous sclerosis patients.
皮膚疾患の主な症状。「紫外線に当たってはいけない病気」
結節性硬化症に多くみられる皮膚の腫瘍や白斑の発症のきっかけは、日焼けなどによる皮膚への刺激やストレスが影響しており、自己免疫として皮膚が白っぽくなってメラニン色素を形成する細胞を攻撃する、遺伝的要因もあるとも言われている。本来ビタミンD3は人の皮膚内で紫外線に当たることで生成される性質を持っている。その上、ビタミンD3が生成されることによってのみしか吸収されないカルシウムやリンが大幅に欠如すると骨粗鬆症などを引き起こしかねない。これによって、ビタミンD3を含むどのようなビタミンD化合物を服用しても皮膚の症状を改善するのは難しいと考える。The main symptoms of skin diseases. "Illness that should not be exposed to UV rays"
Skin tumors and vitiligo that often occur in tuberous sclerosis are triggered by skin irritation and stress caused by sunburn, etc., and attack the cells that form melanin pigments as the skin becomes whitish as autoimmunity It is said that there are genetic factors. Originally vitamin D 3 has the property of being produced by exposure to ultraviolet rays in human skin. Moreover, calcium and phosphorus is not absorbed can lead to such the lack significantly osteoporosis only a by vitamin D 3 is generated. Thus, it is considered difficult to improve skin symptoms no matter what vitamin D compound containing vitamin D 3 is taken.
結節性硬化症に多いとされる血管症状の主な症状
・心臓の血液の流れを邪魔する心筋肥大や不整脈、心不全。
・頬の赤みを帯びた数ミリの盛り上がったニキビ様の顔面血管線維腫。
・血液の圧迫の為に引き起こされる肺病変。・腎臓嚢腫、血管(腎血管筋脂肪腫)
ほぼ全身の血管中に腫瘍細胞が発生しやすい症状と言われている。酸化により老化した血管は使い古したゴム管のように亀裂が入り、あちこちゴムが盛り上がって細くなって流れにくく裂けやすくなっている。この状態で血管中に活性酸素があると食物中の脂肪を過酸化脂質という悪性の物質に変え活性酸化予備軍として、さらに血管中のコレステロールを酸化させる働きをし、血管があらゆる場所で動脈硬化を引き起こす原因となる。
これによって、どんな栄養を摂取しても皮肉なことに腫瘍細胞を成長させる栄養素に変えられてしまうと考えられ、全身の血管中に、いつ爆発するとも分からない爆弾を抱え爆弾が成長していくのを止めることも出来ないでいるような状態である。
上記の参考文献として引用した文献としては
1「結節性硬化症(プリングル病)とは」より 皮膚・結合組織疾患調査研究班
2「医学辞典」より(20数名の医療機関専門医の監修を受けています。)Major symptoms of vascular symptoms often found in tuberous sclerosis: Myocardial hypertrophy, arrhythmia, and heart failure that obstructs blood flow in the heart.
・ Several millimeters of acne-like facial hemangiofibromas with red cheeks.
・ Lung lesions caused by blood pressure.・ Kidney cyst, blood vessel (renal angiomyolipoma)
It is said to be a symptom that tumor cells tend to occur in almost all blood vessels. Blood vessels that have aged due to oxidation are cracked like used rubber tubes, and rubber grows up and down, making it difficult to flow and tear easily. In this state, if there is active oxygen in the blood vessel, it changes the fat in the food to a malignant substance called lipid peroxide, and acts as an active oxidation reserve, further oxidizing cholesterol in the blood vessel, and the blood vessel is arteriosclerosis everywhere Cause.
As a result, it is thought that whatever nutrient is consumed, ironically, it is converted to a nutrient that grows tumor cells, and the bomb grows with a bomb that does not know when it explodes in the blood vessels of the whole body It is in a state that can not be stopped.
The references cited above are as follows: 1 “What is tuberous sclerosis (Pringle disease)” Skin and connective tissue disease research team 2 “Medical dictionary” (under the supervision of more than 20 medical institution specialists) .)
ビタミンD化合物は酸化に反応する性質をもっている。
もし活性酸素が体内中蔓延していたらビタミンD化合物の一部が酸化結合される可能性があり、末梢血管へ運ばれる前にビタミンD化合物の性質が損なわれるだけではなく、攻撃性を持つ事も考えられる。Vitamin D compounds have the property of reacting to oxidation.
If active oxygen is prevalent throughout the body, some of the vitamin D compounds may be oxidatively bound, and not only the properties of the vitamin D compounds are impaired before being transported to the peripheral blood vessels, but they are also offensive Is also possible.
以上に述べた結節性硬化症の改善法では、腫瘍等が発生する体内環境を整えることを手段としている技術が少なく、不足している栄養素を単に補足しているというように考えられる。また、このような体内環境のままでは腫瘍等の成長を抑えるどころか逆に促していく可能性もあると考えられる。このような悪循環に有効な手段で、毎日手軽に取り入れることの出来るものが今まで考えられなかった。 In the method for improving tuberous sclerosis described above, there are few techniques that are used to prepare the internal environment in which tumors and the like are generated, and it seems that the missing nutrients are simply supplemented. In addition, it is considered that there is a possibility that it will be promoted rather than suppressing the growth of tumors and the like in such an internal environment. Until now, there has been no way to think of an effective means for such a vicious circle that can be easily incorporated every day.
そこで、結節性硬化症に多い腫瘍やその他の症状を活性水素の中和させる働きによって進行を抑え、結節性硬化症に有効とされているビタミンD3の効果を高める体内環境を作る為に、毎日摂取しやすい飲料型のビタミンD化合物含有活性水素水とした。Therefore, in order to make the body environment suppressing progression through the action to neutralize the in many tumors and other symptoms of active hydrogen tuberous sclerosis, enhance the effect of vitamin D 3, which is effective in tuberous sclerosis, It was made into the active hydrogen water containing the vitamin D compound of the drink type which is easy to take every day.
まず、活性水素には活性酸素を中和することで抗ガン作用がある。 First, active hydrogen has an anticancer effect by neutralizing active oxygen.
とても簡単な式ではあるが、水素は酸素と化合して水=H2Oになる。
その両方の性質を利用して酸化を抑えることで正常な器官や血液に整え、疾病に対する作用を軽減させるという原理で、結節性硬化症にも全身悪性腫瘍への成長を早期に抑えやすくなると考えられる。Although it is a very simple formula, hydrogen combines with oxygen to form water = H 2 O.
It is thought that it is easy to suppress the growth to systemic malignant tumors early in tuberous sclerosis by the principle of using both of these properties to reduce oxidation by suppressing oxidation and normal organs and blood. It is done.
その為に、ビタミンD化合物を抗ガン作用のある活性水素水に含有させ、ビタミンD化合物が中和された細胞に行き届いたときに正しく吸収されることで結節性硬化症に有効とされているビタミンD3の効果を高めることができるビタミンD化合物含有活性水素水飲料を発明した。For this purpose, vitamin D compounds are contained in active hydrogen water having anticancer activity, and when vitamin D compounds reach the neutralized cells, they are absorbed correctly and are effective for tuberous sclerosis. A vitamin D compound-containing active hydrogen water beverage capable of enhancing the effect of vitamin D 3 was invented.
まず従来の技術[0007]で述べた結節性硬化症に多い腫瘍についてであるが、もし活性水素を日常的に体内に摂取することができれば、細胞核に進入して遺伝子を傷つける活性酸素は少なくなり、変異細胞の発生は何分の一かに減ると言われている。
さらに、自然治癒力や免疫細胞の攻撃力が活性化していれば、仮にガン細胞が生き残ったとしてもガンの芽を非自己と認識して攻撃・全滅してくれる。
その結果、結節性硬化症に多い脳腫瘍と、それによるてんかんその他の痙攣発作、知能低下が抑えられると考える。First, regarding tumors that are common in tuberous sclerosis described in the prior art [0007], if active hydrogen can be taken into the body on a daily basis, the amount of active oxygen that enters the cell nucleus and damages the gene decreases. It is said that the occurrence of mutant cells is reduced by a fraction.
Furthermore, if the natural healing power and the attack power of immune cells are activated, even if the cancer cells survive, they recognize the cancer buds as non-self and attack and annihilate them.
As a result, we think that brain tumors often associated with tuberous sclerosis, epilepsy and other convulsive seizures, and reduced intelligence can be suppressed.
さらに、結節性硬化症の予後は悪く,多くは20歳,30歳代で死亡すると言われているが、この活性酸素による脳種の成長を中和することで抑えることができれば、悪性腫瘍への成長を早期の段階で抑えやすくなるのではないかと考えられる。 Furthermore, the prognosis of tuberous sclerosis is poor, and many are said to die in their 20s and 30s, but if they can be suppressed by neutralizing the growth of brain species caused by this active oxygen, they can become malignant tumors. It is thought that it will be easier to restrain the growth of the company at an early stage.
次に従来の技術[0010]の皮膚疾患についてだが、このメラニン色素の進行を抑える働きも水素水で実証されている。健康な人の老化に伴うシミやシワは活性酸素によって過酸化脂質ができ、皮膚にメラニン色素が沈着することによってできる。 Next, regarding the skin disease of the prior art [0010], the action of suppressing the progression of this melanin pigment has been demonstrated with hydrogen water. Spots and wrinkles associated with the aging of healthy people are formed by the formation of lipid peroxides by active oxygen and the deposition of melanin on the skin.
皮膚疾患の一つの白斑は紫外線を浴びる刺激を与えることで起きる症状ではあるが、白斑がこのメラニン色素の定着を防ごうとする自己免疫として皮膚に影響がでていると考えられているならば、酸化を中和させる水素水の働きで皮膚疾患にも効果があると考えられる。 If one of the skin diseases is a symptom caused by stimulating exposure to ultraviolet rays, if it is thought that the white spot affects the skin as an autoimmunity to prevent the fixation of this melanin pigment It is thought that the action of hydrogen water that neutralizes oxidation also has an effect on skin diseases.
また、ある家族では皮膚疾患の発生が増大する。と言われているがその家庭の生活環境や食習慣にも多少影響しているということが想定される。それならば、活性水素によって体内の血液や細胞から整え、メラニン色素の進行を抑えられる環境を作ることで皮膚への影響が軽減すると考えられる。 Some families also have an increased incidence of skin diseases. However, it is assumed that it has some influence on the living environment and eating habits of the family. Then, it is thought that the effect on the skin is reduced by preparing an environment in which the progress of melanin pigment can be suppressed by adjusting the blood and cells in the body with active hydrogen.
さらに、活性水素水によって中和された正常な皮膚細胞に一緒に運ばれたプロビタミンD3が皮下で紫外線によって老化のシミやシワを発生させることなく正常にビタミンD3となり、色素定着が正常に行われるようになると考えられる。これによって懸念されていたカルシウム不足状態も軽減されていくと考えられる。Furthermore, normally Vitamin D 3, and the dye fixing normal without provitamin D 3 which is entrained in normal skin cells neutralized by active hydrogen water generates the spots and wrinkles of aged UV subcutaneously It is thought that it will be carried out. This is thought to reduce the deficiency of calcium, which has been a concern.
さらに、従来の技術[0007]で述べた結節性硬化症に多い血管障害については、もし、活性酸素が活性水素水によって血液中に侵入しなければ、あるいは早い時期に抗酸化物質で中和されていれば、弾力を失うことなく血管の老化を抑えることができると考えられる。 Furthermore, with regard to the vascular disorders that are common in tuberous sclerosis described in the prior art [0007], if active oxygen does not enter the blood by active hydrogen water, or is neutralized with antioxidants at an early stage. If so, it is thought that aging of blood vessels can be suppressed without losing elasticity.
その結果、血管障害によって引き起こされる狭心症、心筋梗塞、不整脈、脳梗塞、脳出血、顔面血管線維腫、腎血管筋脂肪腫などの発症が大幅に抑えられると考えられる。 As a result, it is considered that the occurrence of angina pectoris, myocardial infarction, arrhythmia, cerebral infarction, cerebral hemorrhage, facial angiofibroma, renal angiomyolipoma, etc. caused by vascular disorders can be significantly suppressed.
そもそも結節性硬化症を起こす遺伝子に異常があると考えられ、結節性硬化症を起こす遺伝子は、染色体9番と16番の上にあることがわかり、
染色体9番の遺伝子は、Tsc1遺伝子。
染色体16番の遺伝子は、Tsc2遺伝子。
と言う。
この遺伝子が作り出すもの(蛋白質)の量が、半分に減ることが原因と考えられている。
人の体は70%の水分と同じように、ほとんどが蛋白質で生成されていると考えられている。もしこの蛋白質が、酸化作用によって過酸化脂質という悪性の物質に変えられて活性酸化予備軍として、さらに血管中の細胞や脂質を酸化させる働きをするならば、急激にこの蛋白質が減ることで結節性硬化症を引き起こすことになる影響は活性水素の働きにより軽減されることが考えられる。In the first place, it seems that there is an abnormality in the gene causing tuberous sclerosis, and the gene causing tuberous sclerosis is found on chromosomes 9 and 16,
The gene of chromosome 9 is the Tsc1 gene.
The gene of chromosome 16 is the Tsc2 gene.
Say.
The cause is thought to be that the amount of protein (protein) produced by this gene is reduced by half.
It is thought that most of the human body is made of protein, like 70% moisture. If this protein is converted into a malignant substance called lipid peroxide by oxidation, it acts as an active oxidation reserve and further oxidizes cells and lipids in blood vessels. It is considered that the effect that causes the sclerosis is alleviated by the action of active hydrogen.
しかし、実際には、50〜60%以上の両親の遺伝子には結節性硬化症にみられる症状が全く見つからない。この場合は、ご両親から遺伝したのではなく、ご両親の精子または卵子の遺伝子にたまたま異常がおこり、子どもさんが発病したと考えられる。
活性酸素の攻撃にあって遺伝子情報を傷つけられると、遺伝子にたまたま異常がおこりガンの原型の変異細胞がでる。
もし環境の変化及びストレス、食生活による影響で遺伝子異常を起こす可能性があるならば、活性水素の働きによってこれらを軽減させることができ、このような病気の子供が生まれる率を少しでも抑えることができるのではないかと考える。
活性水素水の臨床例としての参考文献としては
活性水素水を含有するトラテコの水での改善率 臨床データの記録である。
・エイズ100% ・アレルギー99%
・皮膚疾患89% ・消化器疾患91%
・骨関節炎87% ・糖尿病88%
「ウルグアイのモンテビデオ総合病院」
「難病を克服した奇跡の水は水素水だった!」よりHowever, in reality, no symptoms found in tuberous sclerosis are found in the genes of 50-60% or more of parents. In this case, it is considered that the child was ill because the parent's sperm or ovum gene happened to be abnormal instead of being inherited from the parents.
When genetic information is hurt in the attack of active oxygen, the gene happens to be abnormal, and a prototype cancer cell appears.
If there is a possibility of causing genetic abnormalities due to environmental changes, stress, and dietary influences, these can be reduced by the action of active hydrogen, and the rate at which such sick children are born can be reduced even a little. I think that I can do it.
As a reference as a clinical example of active hydrogen water, the improvement rate of water of tigerko containing active hydrogen water is a record of clinical data.
・ AIDS 100% ・ Allergy 99%
・ Skin disease 89% ・ Gastrointestinal disease 91%
・ 87% osteoarthritis ・ 88% diabetes
"Montevideo General Hospital in Uruguay"
From "Miraculous water overcoming incurable diseases was hydrogen water!"
以下、本発明の実施の形態を活性水素水とビタミンDの性質に基づいて説明する。Hereinafter, embodiments of the present invention will be described based on the properties of active hydrogen water and vitamin D.
それでは、その活性水素水とビタミンD化合物をどうやって一緒にするか?という問題になってくるがビタミンD化合物は脂溶性で水に溶けにくい性質を持っているので分散剤など(トウモロコシデンプン等)何らかの水溶性に加工させる添加物等を加えて生成する方法もある。So how do you combine the active hydrogen water and vitamin D compounds together? However, since vitamin D compounds are fat-soluble and hardly soluble in water, there is a method in which a dispersant or the like (such as corn starch) is added with some water-soluble additives.
例えばアーモンドオイルとココナッツオイルから採れる天然オイル乳化剤や、大豆レシチンから採れる天然オイル分散剤を添加することで水に混ざりやすくし、また混ざった後再び分離しないよう安定させることができる。 For example, by adding a natural oil emulsifier obtained from almond oil and coconut oil or a natural oil dispersant obtained from soybean lecithin, it can be easily mixed with water, and can be stabilized so as not to separate again after mixing.
ではビタミンD化合物をどのくらい含有させるかであるが、1歳未満の乳児では1日25マイクログラム(1.000IU)(IUは国際単位「インターユニット」で、ビタミンDの1IUは約0.025マイクログラム),1歳以上では50マイクログラム(2.000IU)が許容上限摂取量とされているので、その上限50マイクログラム以下を含有させる。 How much vitamin D compound is contained, but for infants under 1 year old 25 micrograms (1.000 IU) per day (IU is the international unit “interunit”, 1 IU of vitamin D is about 0.025 micrograms) Gram), 50 micrograms (2.000 IU) is considered to be the allowable upper limit intake for ages 1 and over, so the upper limit of 50 micrograms or less is contained.
また、ビタミンD化合物を1日500マイクログラム以上過剰摂取し続けると高カルシウム血症等になるので注意が必要である。 In addition, it is necessary to be careful because excessive calcium vitamin compound daily intake of 500 micrograms or more will result in hypercalcemia.
次に、ビタミンD化合物を含みながら活性水素水を作り出すには、ビタミンD化合物の性質を考えて反応させる必要がある。 Next, in order to produce active hydrogen water while containing a vitamin D compound, it is necessary to react in consideration of the properties of the vitamin D compound.
通常ビタミンD化合物が古くなって酸化すると変質することがあり、変質したビタミンDは効果がないばかりか、肝臓などに蓄積され肝不全になりやすく、活性型への変換不全を起こし害を与えることもあるが、本発明は酸化を防ぐ活性水素水に含有させるので酸化の心配がほとんどない。 Ordinarily, vitamin D compounds may deteriorate when oxidized, and the altered vitamin D is not only effective, but it accumulates in the liver and is prone to liver failure, causing damage to the active form due to incomplete conversion. However, since the present invention contains active hydrogen water that prevents oxidation, there is almost no worry about oxidation.
また更に念を押せば、ビタミンEは体内の抗酸化剤として重要な役割を持ち、抗酸化作用があることから、ビタミンEを加えることでビタミンD化合物の酸化を防ぐことができる。ビタミンEの酸化はビタミンCが還元して元に戻してくれるので同時に加えると効果的である。 Furthermore, to be more careful, vitamin E has an important role as an antioxidant in the body and has an antioxidant action. Therefore, the addition of vitamin E can prevent the oxidation of vitamin D compounds. Oxidation of vitamin E is effective when added at the same time because vitamin C reduces and restores it.
それでは、活性水素はどうやって発生させるといいかであるが、市販で販売されている水素発生製品は水素発生元素であるマグネシウムや鉄、ナトリウム金属片などを反応させる方法がある。 Then, it is good to generate active hydrogen, but commercially available hydrogen generating products include a method in which hydrogen generating elements such as magnesium, iron, and sodium metal pieces are reacted.
例えばアルカリ金属の一つであるナトリウム金属片をビーカーに入れ、水を注ぐと活性水素が発生する。 For example, when a piece of sodium metal, which is one of alkali metals, is placed in a beaker and water is poured, active hydrogen is generated.
もし、利用者が再度活性水素を自宅で発生させて飲用したいと思ってこれらの市販品を使用しても、ビタミンD化合物になんら影響を及ぼさないであろう。 If the user wants to regenerate active hydrogen at home and drink it, they will not have any effect on vitamin D compounds.
よって、本品の活性水素は、金属系物質及びアルカリ系物質と水の反応によって得たビタミンD化合物含有水素水としても生成可能である。 Therefore, the active hydrogen of this product can also be generated as vitamin D compound-containing hydrogen water obtained by the reaction of metal-based materials and alkaline materials with water.
活性水素の摂取量は1日1.5リットル〜2リットル中におよそ1.8PPmの溶存分子水素量が望ましい。(およそ1000リットルの水に約0.88グラムの水素)
活性水素を体内に入れても副作用はまったくない。宇宙の中でも最も多い元素と呼ばれるくらい、水素は全ての元素の基本となるような物質で、危険性がないので、常識の範囲内ならば水素自体は多く摂っても全く問題がない物質であるから少し多めに摂ってもよい。
摂取量についての参考文献としては
難病を克服した奇跡の水は水素水だった!より 医学博士/伊藤医院院長 伊藤実喜著The active hydrogen intake is preferably about 1.8 PPm of dissolved molecular hydrogen in 1.5 to 2 liters per day. (Approximately 0.88 grams of hydrogen in approximately 1000 liters of water)
There are no side effects even if active hydrogen is put into the body. As hydrogen is the most abundant element in the universe, it is a substance that is the basis of all elements, and since there is no danger, if it is within the scope of common sense, it is a substance that has no problem at all even if it is consumed in large quantities. You may take a little more from.
As a reference for intake, the water of miracles that overcome incurable diseases was hydrogen water! From Dr. Miki Ito, Ph.D.
また、ガンに有効であると言われている活性水素水で有名な「ルルドの水」、「トラテコの水」の成分によると溶存分子水素量がおよそ0.4〜1.5ppmで、PH値7.5〜9.8の範囲であるから、その有効な下限値を目安として、本発明は1日の摂取目安量を、水素溶存量が0.4〜ppm以上でPH値7.5以上の活性水素水とする。 Moreover, according to the components of “Lourdes water” and “Trateco water”, which are famous for active hydrogen water, which is said to be effective for cancer, the dissolved molecular hydrogen amount is about 0.4 to 1.5 ppm, and the PH value is Since it is in the range of 7.5 to 9.8, with the effective lower limit as a guideline, the present invention provides a daily intake guideline amount of hydrogen dissolved amount of 0.4 to ppm or more and a PH value of 7.5 or more. Of active hydrogen water.
上記のようなビタミンD化合物含有水素水ができれば、発明の効果で説明したように、腫瘍の成長を活性水素水によって活性酸素を中和して抑えることで、悪性腫瘍への成長を早期の段階で抑えやすくなるであろう。 If the vitamin D compound-containing hydrogen water as described above can be obtained, as described in the effect of the invention, the growth of the tumor can be suppressed at an early stage by neutralizing the active oxygen with the active hydrogen water to suppress the growth of the tumor. It will be easier to suppress.
また、活性水素水によってビタミンD化合物自体の肺ガン及び大腸ガンの進行を抑える働きも、より有効に働き出す。 In addition, the action of suppressing the progression of lung cancer and colorectal cancer of the vitamin D compound itself by active hydrogen water works more effectively.
また、活性水素水によって細胞や脂質さらに血管中の細胞や脂質を酸化させる働きをおさえることができれば、細胞や脂質が悪性の過酸化脂質となることなく正常に働き出す。 In addition, if active hydrogen water can suppress the action of oxidizing cells and lipids, as well as cells and lipids in blood vessels, the cells and lipids work normally without becoming malignant lipid peroxides.
さらに、活性水素水によって中和された正常な皮膚細胞に一緒に運ばれたビタミンD化合物が皮下で紫外線によって老化のシミやシワを発生させることなく正常にビタミンD3となり、結節性硬化症の皮膚症状の色素定着が正常に行われるようになるであろう。Furthermore, the vitamin D compound carried together with normal skin cells neutralized with active hydrogen water becomes vitamin D 3 normally without generating aging spots and wrinkles by UV rays under the skin. The pigmentation of skin symptoms will become normal.
以上のように本実施形態によれば、ビタミンD3等を有効成分とするビタミンD化合物を含有して生成したビタミンD化合物含有水素水の形をとれば、結節性硬化症の諸症状やガン腫瘍などの成長を抑えるのに有効的な作用を得られるものである。As described above, according to the present embodiment, various forms of tuberculous sclerosis symptoms and cancer can be obtained by taking the form of vitamin D compound-containing hydrogen water produced by containing vitamin D compounds containing vitamin D 3 and the like as active ingredients. An effective action for suppressing the growth of tumors and the like can be obtained.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006326308A JP2008115143A (en) | 2006-11-01 | 2006-11-01 | Vitamin d compound-containing active hydrogen water |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006326308A JP2008115143A (en) | 2006-11-01 | 2006-11-01 | Vitamin d compound-containing active hydrogen water |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008115143A true JP2008115143A (en) | 2008-05-22 |
Family
ID=39501391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006326308A Pending JP2008115143A (en) | 2006-11-01 | 2006-11-01 | Vitamin d compound-containing active hydrogen water |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2008115143A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013212498A (en) * | 2012-03-07 | 2013-10-17 | Tatehiko Ogawa | Reduction powder, and method of producing the same |
| WO2019039478A1 (en) * | 2017-08-24 | 2019-02-28 | 株式会社Mizkan Holdings | Liquid or semisolid emulsion seasoning, method for manufacturing same and flavor improving method |
-
2006
- 2006-11-01 JP JP2006326308A patent/JP2008115143A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013212498A (en) * | 2012-03-07 | 2013-10-17 | Tatehiko Ogawa | Reduction powder, and method of producing the same |
| WO2019039478A1 (en) * | 2017-08-24 | 2019-02-28 | 株式会社Mizkan Holdings | Liquid or semisolid emulsion seasoning, method for manufacturing same and flavor improving method |
| JP6539792B1 (en) * | 2017-08-24 | 2019-07-03 | 株式会社Mizkan Holdings | Liquid or semi-solid emulsified seasoning, method for producing the same, method for improving flavor |
| JP2019162135A (en) * | 2017-08-24 | 2019-09-26 | 株式会社Mizkan Holdings | Emulsified seasoning in liquid or semi-solid state, manufacturing method thereof, and method for improving flavor |
| EP3639678A4 (en) * | 2017-08-24 | 2020-06-10 | Mizkan Holdings Co., Ltd. | LIQUID OR SEMI-SOLID EMULSIFIED SEASONING AND MANUFACTURING METHOD THEREOF, AND FLAVOR IMPROVEMENT METHOD |
| US11412767B2 (en) | 2017-08-24 | 2022-08-16 | Mizkan Holdings Co., Ltd. | Liquid or semi-solid emulsion seasoning, method for manufacturing same and flavor improving method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5812868B2 (en) | Nutritional supplements to improve vitality, immunity, eye and bone health for individuals over 50 years old | |
| ES2254721T3 (en) | COMPOSITION TO REDUCE THE APPETITE IN MAMMALS UNDERSTANDING PROCIANIDINE | |
| EA017496B1 (en) | Composition for regulating lipid metabolism | |
| KR0145715B1 (en) | N-acetyl glucosamine as a cytoprotective agent | |
| JP2008115143A (en) | Vitamin d compound-containing active hydrogen water | |
| Patel et al. | Calcium affects on vascular endpoints | |
| WO2008003484A2 (en) | Agent containing chrysin and cholic acid for reducing weight, accelerating lipid catabolism, and/or restricting calories | |
| CN101601681A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
| CN110122866A (en) | A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis | |
| US7998500B2 (en) | Nutritional supplement for women | |
| ES2276834T3 (en) | COMPOUNDS THAT INCLUDE A FRACTION OF FITOSTEROL AND / OR OF PHYTOSTANOL AND ASCORBIC ACID AND ITS USE AS WEIGHT REGULATING AGENTS. | |
| Chaudhary et al. | Status of Vitamin D and its correlation with Diabetes in North Gujarat, India: https://doi. org/10.54037/WJPS. 2021.91206 | |
| CN101584706A (en) | Pharmaceutical composition used for reducing blood sugar and blood fat and treating diabetes | |
| CN101264101A (en) | Medicinal composition for preventing birth defect and improving memory in prepotency | |
| CN101628027A (en) | Drug combination for reducing blood sugar and lipid levels and treating diabetes | |
| Pullen | Nutrition in Crohn's disease | |
| CN101584736A (en) | Pharmaceutical composition used for reducing blood sugar and blood fat and treating diabetes | |
| CN101574365A (en) | Drug composition for reducing blood sugar and blood fat | |
| McNamara | Vitamin K2 May Help Prevent Arteriosclerosis and Osteoporosis | |
| CN101579441A (en) | Pharmaceutical composition for lowering blood sugar and blood fat | |
| CN101579444A (en) | Pharmaceutical composition for lowering blood sugar and blood fat | |
| CN101579442A (en) | Pharmaceutical composition for lowering blood sugar and blood fat | |
| CN101590150A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
| CN101244080A (en) | Pharmaceutical combination for preventing birth defect and improving anamnesis | |
| CN101632716A (en) | Pharmaceutical composition for reducing blood glucose |